14. Stress Ulcer Prophylaxis — Evidence Review (REVISE Trial Update)

Quick Recap

Cross-cutting supportive-care protocol — part of the daily ICU bundle. This topic has been substantially resolved by a definitive 2024 trial after nearly a decade of genuine uncertainty (SUP-ICU 2018, PEPTIC 2020) about whether PPI-based stress ulcer prophylaxis was safe in the sickest ICU patients — this protocol reflects that resolution.

1. Definition

Stress-related mucosal disease / stress ulceration: gastroduodenal mucosal injury occurring in critically ill patients, driven by mucosal ischemia and impaired mucosal defense during physiological stress, capable of progressing to clinically significant upper GI bleeding.

Stress ulcer prophylaxis (SUP): pharmacologic acid suppression (proton pump inhibitor [PPI] or histamine-2 receptor antagonist [H2RA]) administered to reduce the risk of clinically important upper GI bleeding in at-risk critically ill patients, most consistently studied and indicated in mechanically ventilated patients.

Clinically important upper GI bleeding: the primary efficacy endpoint used in the definitive modern trials — overt bleeding accompanied by a hemodynamically or clinically significant consequence (e.g., transfusion requirement, intervention, hemodynamic instability), distinct from occult/trivial bleeding that does not meaningfully affect the patient.

2. Pathophysiology

Critical illness reduces splanchnic perfusion and mucosal blood flow, particularly in shock states, impairing the gastric mucosa's normal defenses against acid-mediated injury (mucus/bicarbonate secretion, epithelial turnover, adequate perfusion for repair). This mechanism explains why the highest-risk patients are those with the most severe circulatory compromise — the biological plausibility for benefit is strongest exactly in the population where the safety signal from earlier trials (Section 22) had raised the most concern, creating the central tension this protocol resolves.

Acid suppression (via PPI or H2RA) reduces the acid-mediated component of this mucosal injury risk, but acid suppression itself is not risk-free: it alters gastric pH-dependent bacterial colonization, theoretically increasing risk of ventilator-associated pneumonia (VAP) and Clostridioides difficile infection via reduced gastric acid barrier function — this is the mechanistic basis for the decades-long concern about SUP's risk-benefit balance, now substantially clarified (Section 11/22).

3. Immediate Stabilization (ABCDE) — SUP as a Bundle Element

Not an acute stabilization scenario; functions as a daily bundle-element verification:

Checklist:

4. Focused History

• Ventilation status and expected duration (primary risk/indication driver)
• Prior GI bleeding history, known peptic ulcer disease
• Coagulopathy or concurrent anticoagulant/antiplatelet therapy (compounds bleeding risk)
• Corticosteroid exposure (recognized risk factor for stress ulceration, though not independently a primary indication trigger on its own in the absence of mechanical ventilation)
• Renal/hepatic function (relevant to agent selection and dose adjustment)
• C. difficile risk factors (recent antibiotics, prior C. diff infection) — relevant to the theoretical, now largely unconfirmed, safety concern

5. Comprehensive System-wise Examination

• GI: signs of overt bleeding (hematemesis, melena), abdominal exam for tenderness/distension
• General: hemodynamic stability as it relates to both bleeding risk assessment and mucosal perfusion physiology

POCUS/investigation integration: not a primary component; endoscopy is reserved for actual suspected/confirmed bleeding (cross-reference Upper GI Bleed protocol, GI & Hepatology System) rather than as a screening tool for stress ulceration.

6. Syndrome Identification — Reframed as Indication Classification

• Mechanically ventilated — clear indication: the population with the most robust, recent, definitive trial evidence (REVISE trial, Section 11) supporting PPI-based prophylaxis
• Not mechanically ventilated, otherwise low-risk: evidence for benefit is substantially weaker; universal prophylaxis in this broader ICU population is not well supported and should not be applied reflexively
• Additional risk factors present (coagulopathy, prior GI bleed, high-dose corticosteroids) in a non-ventilated patient: individualized consideration, extrapolating cautiously from the ventilated-patient evidence base rather than assuming direct generalizability

7. Differential Diagnosis (of Upper GI Bleeding Despite/Without Prophylaxis)

Cross-reference Upper GI Bleed protocol (GI & Hepatology System) for the full differential of ICU upper GI bleeding (variceal vs. non-variceal, stress ulceration vs. other causes). This protocol's scope is specifically prevention, not the bleeding workup itself.

8. Severity/Risk Assessment

Primary risk stratifier: mechanical ventilation status — this is the single evidence-supported indication trigger from the most recent, largest, and most rigorous trial (REVISE).

Historically cited additional risk factors (from earlier, smaller studies, now less central to indication decisions given REVISE's clarity): coagulopathy, prior GI bleeding, high-dose corticosteroids, severe burns, traumatic brain/spinal injury, hepatic failure, multiorgan failure — these remain relevant for individualizing decisions in non-ventilated patients but should not be treated as independently equivalent triggers to mechanical ventilation status itself.

9. Investigations

Not primarily a diagnostic workup; relevant labs are those informing bleeding risk generally (coagulation profile, platelet count, hemoglobin trend) and renal/hepatic function for dose adjustment. No specific investigation is required to "diagnose" stress ulceration prospectively — the clinical target is prevention of the bleeding event, not identification of subclinical mucosal injury.

10. Point-of-Care Ultrasound

Not applicable to this protocol.

11. Evidence-Based Management

The Core Question Resolved: Is PPI-Based SUP Safe and Effective in Mechanically Ventilated Patients?

Background — why this was genuinely uncertain for years:

• SUP-ICU trial (Krag et al., NEJM 2018): pantoprazole vs. placebo in ICU patients at risk for GI bleeding — found a reduction in clinically important bleeding, but raised a concerning signal of increased mortality in a subgroup of the most severely ill patients on PPI vs. placebo
• PEPTIC trial (JAMA 2020): PPI vs. H2RA in mechanically ventilated ICU patients — found a trend toward increased mortality with PPI compared to H2RA
• Together, these two trials created genuine, guideline-relevant uncertainty: PPIs appeared to reduce bleeding but possibly at a mortality cost in the sickest patients — a real clinical dilemma, not a settled question, for several years

REVISE trial (Cook et al., NEJM 2024) — the definitive, practice-resolving trial:

• Large, international, multicenter (68 ICUs, 8 countries), triple-blinded RCT, n=4,821 mechanically ventilated adults
• IV pantoprazole 40 mg daily vs. matched placebo
• Primary efficacy outcome: clinically important upper GI bleeding at 90 days — significantly lower with pantoprazole (1% vs. 3.5%)
• Primary safety outcome: 90-day all-cause mortality — no significant difference between groups, directly addressing and substantially resolving the mortality concern raised by SUP-ICU and PEPTIC
• Secondary outcomes: no significant difference in ventilator-associated pneumonia or C. difficile infection between groups
• A contemporaneous updated meta-analysis of 12 RCTs (NEJM Evidence 2024) corroborated these findings — PPI reduces clinically important bleeding with no significant increase in pneumonia or C. difficile colitis across the pooled evidence

Practical synthesis: REVISE substantially resolves the prior uncertainty. For mechanically ventilated ICU patients, IV pantoprazole 40 mg daily is supported by high-certainty, contemporary, adequately powered evidence to reduce clinically important upper GI bleeding, without a demonstrated mortality cost and without significant increase in VAP or C. difficile infection. This represents a genuine, evidence-driven resolution of a question that had real clinical uncertainty for the better part of a decade — many clinicians who had grown cautious about routine PPI-based SUP following SUP-ICU/PEPTIC should revisit that caution in light of REVISE.

Agent Selection

• PPI (pantoprazole 40 mg IV daily) is the evidence-preferred agent based on REVISE and the corroborating meta-analysis
• H2RAs remain an alternative where PPI is unavailable or contraindicated, though PEPTIC's mortality-trend signal (PPI vs. H2RA) should be interpreted in light of REVISE's larger, more definitive, and reassuring placebo-controlled data — REVISE did not directly re-test PPI vs. H2RA, so the PEPTIC signal is not fully superseded on that specific comparison, but the overall weight of evidence now favors PPI as the default first-line agent
• Sucralfate: older agent, generally inferior efficacy to PPI/H2RA in modern comparative data and not recommended as first-line

Indication and Duration

• Primary, evidence-clearest indication: mechanically ventilated ICU patients
• Discontinue SUP once mechanical ventilation is no longer required — do not continue by default through extubation and general ward transfer without an explicit ongoing indication (this is a recognized, common source of unnecessary prolonged PPI exposure post-ICU)
• Do not apply universal SUP to all ICU patients regardless of ventilation status — the evidence base is specifically strongest for the ventilated population

12. Organ Support

Not directly an organ-support topic; interacts with mechanical ventilation status as the primary indication driver (Section 11) and with overall GI/nutritional management (cross-reference Nutrition Support in Critical Illness protocol).

13. Disease-Specific Therapy

• Pantoprazole 40 mg IV once daily — evidence-preferred first-line agent for mechanically ventilated patients per REVISE
• H2RA (e.g., famotidine) as an alternative where PPI is unavailable/contraindicated
• Avoid sucralfate as first-line given inferior modern comparative efficacy data

14. Consultation Matrix

15. Monitoring Framework

• Clinical: daily reassessment of ongoing mechanical ventilation status as the primary indication trigger
• Escalation triggers: any overt GI bleeding despite prophylaxis — cross-reference Upper GI Bleed protocol for full workup
• De-escalation criteria: extubation/discontinuation of mechanical ventilation → discontinue SUP unless another specific, explicit indication exists

16. ICU Bundle Checklist (Daily)

17. Complications

Early:

• Breakthrough clinically important upper GI bleeding despite prophylaxis (reduced but not eliminated risk — 1% event rate on pantoprazole in REVISE, not zero)
• Theoretical VAP/C. difficile risk — not confirmed as significantly increased in the definitive modern trial (REVISE) or corroborating meta-analysis

Late:

• Unnecessary prolonged PPI exposure post-ICU/post-extubation if discontinuation is not actively addressed — a recognized, common, avoidable practice gap with its own (separate, longer-term) risk considerations outside the acute ICU context

Prevention: appropriate indication-based initiation (mechanically ventilated patients), active discontinuation at extubation

Rescue: standard Upper GI Bleed protocol management if breakthrough bleeding occurs

18. Escalation & De-escalation

Escalation: breakthrough clinically important upper GI bleeding → full Upper GI Bleed protocol workup and management, not simply an SUP agent/dose change.

De-escalation: discontinue SUP at extubation/discontinuation of mechanical ventilation unless another explicit indication exists — this should be an active, documented decision, not passive continuation.

19. ICU Discharge Criteria (SUP-Relevant Context)

Cross-reference ICU Discharge Criteria & Step-Down protocol. SUP-specific consideration: explicit decision documented and communicated at transfer regarding whether SUP should continue (only if a specific ongoing indication exists) or be discontinued — do not let a PPI ordered for ICU-specific mechanical-ventilation-related SUP silently continue indefinitely post-transfer without active reassessment.

20. Documentation & Medicolegal Checklist

• Indication for SUP (mechanical ventilation status) documented at initiation
• Agent selection rationale documented, particularly if H2RA or sucralfate chosen over PPI
• Discontinuation decision and rationale documented at extubation
• Any breakthrough GI bleeding event documented with full workup per Upper GI Bleed protocol

21. Key Guidelines

• Current practice reflects the REVISE trial (2024) as the definitive, most recent, highest-quality evidence source for this specific question; formal society guideline updates incorporating REVISE should be checked for the most current graded recommendations, as REVISE postdates many existing guideline documents

22. Landmark Trials

23. Controversies

• This topic has moved from genuine controversy to substantial resolution — worth explicitly noting as a rare example in critical care where a single large, well-designed, adequately powered trial (REVISE) meaningfully settled years of legitimate clinical uncertainty (SUP-ICU/PEPTIC) rather than adding another data point to an unresolved debate. Clinicians who adopted a more cautious PPI-avoidance posture in response to SUP-ICU/PEPTIC should specifically revisit that stance in light of REVISE.
• PPI vs. H2RA head-to-head: REVISE was placebo-controlled, not a direct PPI-vs-H2RA re-test — PEPTIC's mortality-trend signal on that specific comparison is not directly superseded by REVISE, so some residual uncertainty remains on the precise PPI-vs-H2RA question even as the PPI-vs-placebo question is now well resolved.
• Generalizability beyond mechanically ventilated patients: REVISE's population was specifically mechanically ventilated adults; extrapolation to non-ventilated ICU patients with other risk factors (coagulopathy, corticosteroids) should remain cautious rather than assuming identical risk-benefit applies.
• Post-ICU PPI discontinuation: not a controversy in the evidence sense, but a persistent, documented practice gap — PPIs initiated for ICU-specific SUP indications are frequently continued unnecessarily post-discharge without active reassessment, an avoidable prescribing inertia issue distinct from the acute ICU indication question this protocol otherwise resolves.

24. References

1. Cook D, Deane A, Lauzier F, et al; REVISE Investigators. Stress ulcer prophylaxis during invasive mechanical ventilation. N Engl J Med. 2024;391(1):9-20.
2. Krag M, Marker S, Perner A, et al; SUP-ICU Trial Group. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med. 2018;379(23):2199-2208.
3. PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, Irish Critical Care Trials Group. Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive mechanical ventilation: the PEPTIC randomized clinical trial. JAMA. 2020;323(7):616-626.
4. Wang Y, Parpia S, Ge L, et al. Proton pump inhibitors to prevent gastrointestinal bleeding — an updated meta-analysis. NEJM Evid. 2024;3(7):EVIDoa2400134.
5. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med. 1998;338(12):791-797.
6. The Washington Manual of Critical Care, 4th ed. 2025 — relevant GI prophylaxis content.
7. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant stress ulcer prophylaxis content.